* current participation in another therapeutic clinical trial for covid-19; * invasive mechanical ventilation; * expected survival \< 24 hours based on clinical assessment (however, the study does not exclude critically ill patients who are not, due to resource limitations, candidates for critical care admission and/or mechanical ventilation); * known hypersensitivity to immunoglobulin or any components of the formulation;

* current participation in another therapeutic clinical trial for covid-19; * invasive mechanical ventilation; * expected survival \< 24 hours based on clinical assessment (however, the study does not exclude critically ill patients who are not, due to resource limitations, candidates for critical care admission and/or mechanical ventilation); * known hypersensitivity to immunoglobulin or any components of the formulation;

- current participation in another therapeutic clinical trial for covid-19; - invasive mechanical ventilation; - expected survival < 24 hours based on clinical assessment (however, the study does not exclude critically ill patients who are not, due to resource limitations, candidates for critical care admission and/or mechanical ventilation); - known hypersensitivity to immunoglobulin or any components of the formulation;

- current participation in another therapeutic clinical trial for covid-19; - invasive mechanical ventilation; - expected survival < 24 hours based on clinical assessment (however, the study does not exclude critically ill patients who are not, due to resource limitations, candidates for critical care admission and/or mechanical ventilation); - known hypersensitivity to immunoglobulin or any components of the formulation;